Sorrento Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$365.3M
Industry:Biotech
Founded:N/A
Lead Investor(s):Oaktree Capital Management

Industry Ranking

Estimated Revenue & Financials

  • Sorrento Therapeutics's estimated annual revenue is currently $21.2M per year.
  • Sorrento Therapeutics received $150.0M in venture funding in November 2018.
  • Sorrento Therapeutics's estimated revenue per employee is $103,887
  • Sorrento Therapeutics's total funding is $365.3M.

Employee Data

  • Sorrento Therapeutics has 204 Employees.
  • Sorrento Therapeutics grew their employee count by -7% last year.
  • Sorrento Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Advertise Here
DiaCarta
$7M4510%N/A-N/A
Geron Corporati...
N/A205N/AN/A-N/A
Rigel Pharmaceu...
$46.8M3024%N/A-N/A
Althea Technolo...
$22.3M144N/AN/A-N/A
INOVA Diagnosti...
$44.3M286N/AN/A-N/A
10X Genomics
$101.2M65346%N/A-N/A
ProTrials Resea...
$33.3M2153%N/A-N/A
Advanced Cell D...
$28.7M1858%N/A-N/A
The J. Craig Ve...
$39.4M254N/AN/A-N/A
CellMax Life
$6.5M4214%N/A-N/A
Missing a competitor? Contribute!?
Submit

Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. Sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical CAR-T therapies targeting solid tumors.

keywords:N/A

204

Number of Employees

$21.2M

Revenue (est)

1

Current Jobs

-7%

Employee Growth %

$365.3M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Sorrento Therapeutics News

12-Sep-19 - Why Sorrento Therapeutics, Inc. (SRNE) Stock is Up Almost 3.88% Today

What just happened? Sorrento Therapeutics, Inc. (NASDAQ:SRNE) stock value has climbed by nearly 3.88% or (0.09 points) to $2.41 from its ...

12-Sep-19 - Sorrento Therapeutics (NASDAQ:SRNE) and National Research (NASDAQ:NRC) Head to Head Comparison

Sorrento Therapeutics (NASDAQ:SRNE) and National Research (NASDAQ:NRC) are both small-cap medical companies, but which is the ...

12-Sep-19 - Sorrento Therapeutics Inc (NASDAQ:SRNE) Institutional Investors Sentiment Index Up in Q2 2019

Sorrento Therapeutics Inc (NASDAQ:SRNE) institutional sentiment increased to 2 in Q2 2019. Its up 0.68, from 1.32 in 2019Q1. The ratio has ...

Sorrento Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-28$30.0MUndisclosedArticle
2013-10-31$34.6MUndisclosedAegis Capital CorpArticle
2014-05-15$25.0MUndisclosedAegis Capital CorpArticle
2016-04-12$150.0MUndisclosedAlly Bridge GroupArticle
2016-05-03$10.0MUndisclosedYuhan CorporationArticle
2016-06-14$150.0MUndisclosedMultipleArticle
2016-11-29$75.0MUndisclosedHercules Capital, Inc.Article
2017-04-20$43.5MUndisclosedCantor Fitzgerald & CoArticle
2018-11-09$150.0MUndisclosedOaktree Capital ManagementArticle

Sorrento Therapeutics Executive Hires

DateNameTitleReference
2009-10-28Martina MolsbergenVP Business Development VArticle
2014-01-09Amar SinghEVP/Chief Business OfficerArticle
2014-01-10William S. MarthChairmanArticle
2014-03-04Mike RoyalSVP Clinical DevelopmentArticle
2015-03-31George NgEVP/Chief Legal OfficerArticle
2015-10-20Jeffrey SuEVP/COOArticle
2016-04-06Kevin M. HerdeEVP/CFOArticle
2016-08-16Jerome ZeldisCMO & President of Clinical DevelopmentArticle
2016-09-14Miranda ToledanoEVP Corporate Development/President Of LA CellArticle

Sorrento Therapeutics Acquisitions

DateCompany NameAmountNotesReference
2013-12-20Concortis Biosystems, CorpStock Deal-CompleteArticle